Barclays
ADCT icon

Barclays’s ADC Therapeutics ADCT Stock Holding History

Barclays’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Buy
94,264
+47,929
+103% +$140K ﹤0.01% 4035
2026
Q1 		$174K Sell
46,335
-115,051
-71% -$454K ﹤0.01% 3772
2025
Q4 		$570K Buy
161,386
+30,926
+24% +$125K ﹤0.01% 3770
2025
Q3 		$522K Sell
130,460
-14,947
-10% -$47.1K ﹤0.01% 3785
2025
Q2 		$390K Buy
145,407
+44,373
+44% +$93.3K ﹤0.01% 3898
2025
Q1 		$142K Sell
101,034
-40,461
-29% -$68.8K ﹤0.01% 4252
2024
Q4 		$282K Buy
141,495
+13,756
+11% +$36K ﹤0.01% 4145
2024
Q3 		$402K Buy
127,739
+93,890
+277% +$296K ﹤0.01% 3907
2024
Q2 		$107K Buy
+33,849
New +$135K ﹤0.01% 3873
2023
Q3 		– Sell
-314,925
Closed -$677K – 4578
2023
Q2 		$677K Sell
314,925
-19,347
-6% -$43.5K ﹤0.01% 2563
2023
Q1 		$652K Buy
+334,272
New +$1.23M ﹤0.01% 3071

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays's ADCT Position: Q2 2026 in Review

Barclays increased its ADC Therapeutics (ADCT) stake by 103% in Q2 2026, buying an estimated $140K and bringing the position to 94,264 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #4035.

Barclays first reported a position in ADCT in Q1 2023 and has held it in 11 quarters since. The position peaked at $677K in Q2 2023. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Barclays held 94,264 shares of ADC Therapeutics worth $101K as of Q2 2026.
  • Barclays bought 47,929 ADC Therapeutics shares in Q2 2026, an estimated $140K.
  • ADC Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4035 holding.
  • Barclays first reported a position in ADC Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • Barclays's ADC Therapeutics position peaked at $677K in Q2 2023.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.